Belly Fat Linked to Early Alzheimer's Biomarkers
Research reveals a strong correlation between increased visceral abdominal fat and the presence of amyloid plaques and tau tangles in the brain, key Alzheimer's biomarkers, even before cognitive decline is evident; reducing belly fat may be a crucial preventative strategy.
Belly Fat Linked to Early Alzheimer's Biomarkers
Research reveals a strong correlation between increased visceral abdominal fat and the presence of amyloid plaques and tau tangles in the brain, key Alzheimer's biomarkers, even before cognitive decline is evident; reducing belly fat may be a crucial preventative strategy.
Progress
44% Bias Score
Zepbound Shows 47% Greater Weight Loss Than Wegovy in Obesity Trial
A clinical trial showed that adults using the obesity drug Zepbound lost 47% more weight on average than those using Wegovy after 18 months, achieving an average weight loss of 50 pounds compared to 33 pounds, respectively.
Zepbound Shows 47% Greater Weight Loss Than Wegovy in Obesity Trial
A clinical trial showed that adults using the obesity drug Zepbound lost 47% more weight on average than those using Wegovy after 18 months, achieving an average weight loss of 50 pounds compared to 33 pounds, respectively.
Progress
48% Bias Score
UK Junk Food Ad Ban: McDonald's Fries Deemed Healthier Than Yogurt
The UK government will restrict junk food advertising using a formula classifying McDonald's fries as healthy but some yogurts and porridge as unhealthy, sparking criticism from experts who warn of consumer confusion.
UK Junk Food Ad Ban: McDonald's Fries Deemed Healthier Than Yogurt
The UK government will restrict junk food advertising using a formula classifying McDonald's fries as healthy but some yogurts and porridge as unhealthy, sparking criticism from experts who warn of consumer confusion.
Progress
52% Bias Score
US to Subsidize Obesity Medications for Millions
The US will spend $35 billion over 10 years to subsidize Wegovy and Mounjaro for millions of Americans with a BMI of 30 or higher, aiming to reduce obesity-related healthcare costs.
US to Subsidize Obesity Medications for Millions
The US will spend $35 billion over 10 years to subsidize Wegovy and Mounjaro for millions of Americans with a BMI of 30 or higher, aiming to reduce obesity-related healthcare costs.
Progress
40% Bias Score
Weight-Loss Drugs: Economic Benefits and NHS Strain
Two weight-loss injections, Wegovy and Monjaro, are showing promise in helping obese people lose weight and return to work, but their increased use strains the NHS and raises concerns about long-term effects and equitable access.
Weight-Loss Drugs: Economic Benefits and NHS Strain
Two weight-loss injections, Wegovy and Monjaro, are showing promise in helping obese people lose weight and return to work, but their increased use strains the NHS and raises concerns about long-term effects and equitable access.
Progress
36% Bias Score
Early Puberty in Young Girls: A Growing Concern
The article discusses the increasing incidence of precocious puberty in young girls in India, highlighting the concerns of parents and the medical professionals trying to understand and address this phenomenon.
Early Puberty in Young Girls: A Growing Concern
The article discusses the increasing incidence of precocious puberty in young girls in India, highlighting the concerns of parents and the medical professionals trying to understand and address this phenomenon.
Progress
20% Bias Score
England's NHS Announces 12-Year Rollout Plan for Mounjaro Weight-Loss Drug
The National Institute for Health and Care Excellence (NICE) announced a 12-year rollout plan for the weight-loss drug Mounjaro on the NHS in England, prioritizing 220,000 patients in the first three years due to budgetary constraints, affecting 3.4 million eligible individuals.
England's NHS Announces 12-Year Rollout Plan for Mounjaro Weight-Loss Drug
The National Institute for Health and Care Excellence (NICE) announced a 12-year rollout plan for the weight-loss drug Mounjaro on the NHS in England, prioritizing 220,000 patients in the first three years due to budgetary constraints, affecting 3.4 million eligible individuals.
Progress
48% Bias Score
Zepbound Outperforms Wegovy in 72-Week Weight Loss Trial
A new, yet un-peer-reviewed study shows Eli Lilly's Zepbound (tirzepatide) enabled 20% weight loss in 72 weeks among 751 obese or overweight participants, exceeding Wegovy's (semaglutide) under 14% weight loss; this translates to approximately 50 pounds lost with Zepbound versus 33 pounds with Wegov...
Zepbound Outperforms Wegovy in 72-Week Weight Loss Trial
A new, yet un-peer-reviewed study shows Eli Lilly's Zepbound (tirzepatide) enabled 20% weight loss in 72 weeks among 751 obese or overweight participants, exceeding Wegovy's (semaglutide) under 14% weight loss; this translates to approximately 50 pounds lost with Zepbound versus 33 pounds with Wegov...
Progress
40% Bias Score
UK Junk Food Ad Ban: Minimal Impact Projected
The UK government banned junk food advertising online and before 9pm on TV starting October 2024 to combat childhood obesity; however, the projected impact is minimal, reducing children's daily calorie intake by only 2.1 calories.
UK Junk Food Ad Ban: Minimal Impact Projected
The UK government banned junk food advertising online and before 9pm on TV starting October 2024 to combat childhood obesity; however, the projected impact is minimal, reducing children's daily calorie intake by only 2.1 calories.
Progress
68% Bias Score
El auge de fármacos contra la obesidad reduce las cirugías bariátricas en Estados Unidos
El uso de agonistas del receptor GLP-1 para tratar la obesidad aumentó un 123% en Estados Unidos entre 2022 y 2023, mientras que las cirugías bariátricas disminuyeron un 25%, planteando un cambio en las estrategias terapéuticas y la necesidad de evaluar la combinación de ambos tratamientos.
El auge de fármacos contra la obesidad reduce las cirugías bariátricas en Estados Unidos
El uso de agonistas del receptor GLP-1 para tratar la obesidad aumentó un 123% en Estados Unidos entre 2022 y 2023, mientras que las cirugías bariátricas disminuyeron un 25%, planteando un cambio en las estrategias terapéuticas y la necesidad de evaluar la combinación de ambos tratamientos.
Progress
40% Bias Score
Weight-Loss Injections Strain UK NHS
Two injectable weight-loss medications, Wegovy and Mounjaro, are showing efficacy in the UK, but concerns exist regarding increased demand on the NHS, limited availability, and private market costs ranging from £200-£300 per pen.
Weight-Loss Injections Strain UK NHS
Two injectable weight-loss medications, Wegovy and Mounjaro, are showing efficacy in the UK, but concerns exist regarding increased demand on the NHS, limited availability, and private market costs ranging from £200-£300 per pen.
Progress
20% Bias Score
Study Investigates Impact of Ultra-Processed Foods on Health
A study investigates the effects of ultra-processed foods on health, particularly weight gain and obesity, with the potential to inform future dietary guidelines.
Study Investigates Impact of Ultra-Processed Foods on Health
A study investigates the effects of ultra-processed foods on health, particularly weight gain and obesity, with the potential to inform future dietary guidelines.
Progress
32% Bias Score